BNTX:NSD-BioNTech SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 161.66

Change

-7.57 (-4.47)%

Market Cap

USD 47.53B

Volume

3.53M

Avg Analyst Target

USD 322.55 (+99.52%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BioNTech SE (BNTX) Stock Analysis:
Based on the BioNTech SE stock forecasts from 12 analysts, the average analyst target price for BioNTech SE is USD 322.55 over the next 12 months. BioNTech SE’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of BioNTech SE is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, BioNTech SE’s stock price was USD 161.66. BioNTech SE’s stock price has changed by -59.21% over the past week, -125.62% over the past month and +56.60% over the last year.

About

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 th ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A
RPRX Royalty Pharma plc

-0.35 (-0.87%)

USD17.17B 20.75 11.89

ETFs Containing BNTX

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-2.15 (-1.29%)

USD0.57B
BBP ETFis Series Trust I - Vi.. 0.00 % 0.79 %

-0.34 (-0.79%)

USD0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-1.41 (-2.19%)

USD0.19B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

-1.01 (-0.68%)

USD1.71B
FPXI First Trust International.. 0.00 % 0.70 %

+0.35 (+0.66%)

USD0.88B
FPXE First Trust IPOX Europe E.. 0.00 % 0.70 %

+0.07 (+0.25%)

USD0.01B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-0.48 (-1.33%)

USD0.33B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.10 %

+0.19 (+0.30%)

USD0.08B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.06 (-1.03%)

USD0.47B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

-0.10 (-2.20%)

USD0.47B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.11 (-1.79%)

USD0.04B
GERM ETF Managers Trust - ETFM.. 0.00 % 0.68 %

-0.42 (-1.44%)

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-34.27 (-2.50%)

N/A
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

-0.62 (-3.32%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

-0.23 (-1.08%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.29% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.29% 3% F 2% F
Trailing 12 Months  
Capital Gain 56.60% 95% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.60% 95% A 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 150.72% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.72% 92% A- 95% A
Risk Return Profile  
Volatility (Standard Deviation) 160.22% 15% F 9% F
Risk Adjusted Return 94.07% 98% A+ 93% A
Market Capitalization 47.53B 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.15 53% F 82% B-
Price/Book Ratio 6.32 19% F 20% F
Price / Cash Flow Ratio -3,527.78 100% A+ 98% A+
EV/EBITDA 5.67 36% F 77% C+
Management Effectiveness  
Return on Equity 15.55% 97% A+ 81% B-
Return on Invested Capital 6.58% 87% B+ 69% D+
Return on Assets 81.62% 100% A+ 100% A+
Debt to Equity Ratio 16.84% 44% F 62% D-
Technical Ratios  
Short Ratio 0.69 84% B 81% B-
Short Percent 2.94% 63% D 47% F
Beta -1.38 99% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.